Do comprehensive medication reviews hold the key to enhancing adherence to COPD medications?
A recent study used multilayer omic networks to help identify molecularly distinct groups of patients with COPD in an effort to explain why patients with similar presentations might have different and distinct clinical courses.
Recommendations for interpreting spirometry severity classifications have recently been updated to include race-neutral reference equations and z scores. These researchers found that the new classification thresholds affect severity classification in the same proportion for White and Black patients with COPD and are appropriately associated with clinical risk.
Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity.
Data from the FDA adverse event reporting system were reviewed to investigate reports of cardiovascular adverse events observed in patients receiving treatment with long-acting muscarinic receptor antagonists.
Early evidence suggests promise for a novel COPD treatment using autologous P63+ lung progenitor cell. This small study found the bronchoscopic transplantation of cultured P63+ cells to be safe and well-tolerated.
According to these findings, individuals with alpha-1 antitrypsin deficiency associated COPD report impairments in physical health but not mental health.
Heads up: These investigators found that TB survivors had a higher incidence of COPD and were more likely than control subjects to be hospitalized for COPD-related complications.